


Specification

Please replace formula (XII) in the specification starting on page 1, line 26 and ending on page 4, line 11, as follows:

5

Disclosed is a 9-arylsulfone of the formula (XII)



where R_3 is:

- (1) -H,
- (2) C_1 - C_4 alkyl,
- (3) C_0 - C_4 alkyl- ϕ where the - ϕ substituent is optionally substituted with 1 or 2
 - (a) -F, -Cl, -Br, -I,
 - (b) -O- R_{3-1} where R_{3-1} is:
 - H,
 - C_1 - C_4 alkyl,
 - ϕ ,
 - (c) -CF₃,
 - (d) -CO-NR₃₋₂R₃₋₃ where R_{3-2} and R_{3-3} are -H and C_1 - C_4 alkyl, and where R_{3-2} and R_{3-3} are taken with the attached nitrogen atom to form a ring selected from the group consisting of 1-pyrrolidinyl, 1-piperazinyl and 1-morpholinyl,
 - (e) -NH-SO₂-R₃₋₄ where R_{3-4} is -H and C_1 - C_4 alkyl,
 - (f) -NR₃₋₂R₃₋₃ where R_{3-2} and R_{3-3} are as defined above,
 - (g) -NR₃₋₄-CO-R₃₋₄ where R_{3-4} is as defined above,
 - (h) -SO₂-NR₃₋₂R₃₋₃ where R_{3-2} and R_{3-3} are as defined above,
 - (i) -C \equiv N,
 - (j) -NO₂,

where R_N is:

- (1) -H,
- (2) C_1 - C_4 alkyl,

(3) C₀-C₄ alkyl- ϕ where the - ϕ substituent is optionally substituted with 1 or 2

(a) -F, -Cl, -Br, -I,

(b) -O-R_{N-1} where R_{N-1} is

-H,

C₁-C₄ alkyl,

- ϕ ,

(c) -CF₃,

(d) -CO-NR_{N-2}R_{N-3} where R_{N-2} and R_{N-3} are -H and C₁-C₄ alkyl, and

where R₃₋₂ and R₃₋₃ are taken with the attached nitrogen atom to form a ring selected

from the group consisting of 1-pyrrolidinyl, 1-piperazinyl and 1-morpholinyl,

(e) -NH-SO₂-R_{N-4} where R_{N-4} is -H and C₁-C₄ alkyl,

(f) -NR_{N-2}R_{N-3} where R_{N-2} and R_{N-3} are as defined above,

(g) -NR_{N-4}-CO-R_{N-4} where R_{N-4} is as defined above,

(h) -SO₂-NR_{N-2}R_{N-3} where R_{N-2} and R_{N-3} are as defined above,

(i) -C \equiv N,

(j) -NO₂,

where R_X is:

(1) -H

(2) -F, -Cl, -Br, -I,

(3) -O-R_{X-1} where R_{X-1} is:

-H,

C₁-C₄ alkyl,

- ϕ ,

(4) -CF₃,

(5) -CO-NR_{X-2}R_{X-3} where R_{X-2} and R_{X-3} are -H and C₁-C₄ alkyl, and where

R_{[X]X-2} and R_{[X]X-3} are taken with the attached nitrogen atom to form a ring selected

from the group consisting of 1-pyrrolidinyl, 1-piperazinyl and 1-morpholinyl,

(6) -NH-SO₂-R_{X-4} where R_{X-4} is -H and C₁-C₄ alkyl,

(7) -NR_{X-2}R_{X-3} where R_{X-2} and R_{X-3} are as defined above,

(8) -NR_{X-4}-CO-R_{X-4} where R_{X-4} is as defined above,

(9) -SO₂-NR_{X-2}R_{X-3} where R_{X-2} and R_{X-3} are as defined above,

(10) -C \equiv N,

(11) -NO₂;

where R_9 is:

- (1) -H,
(2) -F, -Cl,
(3) C_1 - C_4 alkyl,
5 (4) C_1 - C_3 alkoxy,
(5) $-CF_3$,
(6) C_0 - C_4 alkyl- ϕ where the $-\phi$ substituent is optionally substituted with 1 or 2
(a) -F, -Cl, -Br, -I,
(b) $-O-R_{9.1}$ where $R_{9.1}$ is:
10 -H,
 C_1 - C_4 alkyl,
 $-\phi$,
(c) $-CF_3$,
(d) $-CO-NR_{9.2}R_{9.3}$ where $R_{9.2}$ and $R_{9.3}$ are -H and C_1 - C_4 alkyl, and
15 where $R_{9.2}$ and $R_{9.3}$ are taken with the attached nitrogen atom to form a ring selected
from the group consisting of 1-pyrrolidinyl, 1-piperazinyl and 1-morpholinyl,
(e) $-NH-SO_2-R_{9.4}$ where $R_{9.4}$ is -H and C_1 - C_4 alkyl,
(f) $-NR_{9.2}R_{9.3}$ where $R_{9.2}$ and $R_{9.3}$ are as defined above,
(g) $-NR_{9.4}-CO-R_{9.4}$ where $R_{9.4}$ is as defined above,
20 (h) $-SO_2-NR_{9.2}R_{9.3}$ where $R_{9.2}$ and $R_{9.3}$ are as defined above,
(i) $-C\equiv N$,
(j) $-NO_2$
(7) $-OR_{9.1}$ where $R_{9.1}$ is as defined above,
(8) $-CO-NR_{9.2}R_{9.3}$ where $R_{9.2}$ and $R_{9.3}$ are as defined above,
25 (9) $-NR_{9.2}R_{9.3}$ where $R_{9.2}$ and $R_{9.3}$ are as defined above,
(10) $-NH-SO_2-R_{9.4}$ where $R_{9.4}$ is as defined above,
(11) $-NH-CO_2-R_{9.2}$ where $R_{9.2}$ is as defined above,

and pharmaceutically acceptable salts thereof.

Please replace the paragraph on page 6 starting at line 4 and ending on line 11 with the following:

The 9-arylsulfones (XI) are amines, and as such form acid addition salts when
5 reacted with acids of sufficient strength. Pharmaceutically acceptable salts include salts of both inorganic and organic acids. The pharmaceutically acceptable salts are preferred over the corresponding free amines since they produce compounds which are more water soluble and more crystalline. The preferred pharmaceutically acceptable salts include salts of the following acids methanesulfonic, hydrochloric, hydrobromic,
10 sulfuric, phosphoric, nitric, benzoic, citric, tartaric, fumaric, maleic, $\text{CH}_3-(\text{CH}_2)_n-\text{COOH}$ where n is 0 thru 4, $\text{HOOC}-(\text{CH}_2)_{[N]}-\text{COOH}$ where n is as defined above.

Please amend claims 24-25 as follows: